Shots:
- AbbVie has reported final analysis data from P-III (MIRASOL) trial assessing Elahere vs CT in FRα+ PROC pts (n= 453) who had previously received 1-3L of therapy
- At 30.5mos. mFU, trial showed 37% improved PFS (mPFS: 5.59 vs 3.98mos.) & superior ORR (41.9% vs 15.9%), while mOS was 16.85 vs 13.34mos., with 32% reduced death risk. DoR & safety remained consistent with primary analysis at 13.1mos. mFU
- Additionally, separate analysis from P-III (MIRASOL) trial assessing impact of Elahere treatment-emergent ocular events on pts-reported HRQoL was presented at SGO 2025
Ref: AbbVie | Image: AbbVie
Related News:- AbbVie Reports the CHMP’s Positive Opinion of Elahere (Mirvetuximab Soravtansine) to Treat Ovarian Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
